These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 36539295)

  • 21. Hepatitis C during disease modifying therapy with Fingolimod for Relapsing Remitting Multiple Sclerosis: diagnosis and treatment.
    Aslanyan A; Anwar-Hashim Z; Siripurapu R; Mihalova T
    BMJ Case Rep; 2021 Feb; 14(2):. PubMed ID: 33637491
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lymphomatoid papulosis: A cutaneous lymphoproliferative disorder in a patient on fingolimod for multiple sclerosis.
    Samaraweera AP; Cohen SN; Akay EM; Evangelou N
    Mult Scler; 2016 Jan; 22(1):122-4. PubMed ID: 26219664
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ventricular tachycardia after initiation of fingolimod.
    Elounais F; Aburahma A; Alkotob ML; Al Hadidi S
    BMJ Case Rep; 2017 Sep; 2017():. PubMed ID: 28954755
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Disease reactivation after fingolimod cessation in Multiple Sclerosis patients with pregnancy desire: A retrospective study.
    Callens A; Leblanc S; Le Page E; Edan G; Jourdain A; Coustans M; Wiertlewski S; Laplaud D; Videt D; Lallement F; Leray E; Michel L
    Mult Scler Relat Disord; 2022 Oct; 66():104066. PubMed ID: 35908450
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fingolimod-associated macular oedema.
    Jasani KM; Sharaf N; Rog D; Aslam T
    BMJ Case Rep; 2017 Jun; 2017():. PubMed ID: 28619738
    [No Abstract]   [Full Text] [Related]  

  • 26. Improvement of macular edema without discontinuation of fingolimod in a patient with multiple sclerosis: A case report.
    Akiyama H; Suzuki Y; Hara D; Shinohara K; Ogura H; Akamatsu M; Hasegawa Y
    Medicine (Baltimore); 2016 Jul; 95(29):e4180. PubMed ID: 27442641
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ventricular arrhythmia in a male MS patient on fingolimod.
    van Pesch V; Marchandise S; El Sankari S; Sindic C
    Acta Neurol Belg; 2015 Mar; 115(1):77-9. PubMed ID: 24710722
    [No Abstract]   [Full Text] [Related]  

  • 28. BASAL CELL CARCINOMA AND SQUAMOUS CELL CARCINOMA IN A PATIENT TREATED WITH FINGOLIMOD FOR MULTIPLE SCLEROSIS - A CASE REPORT AND LITERATURE REVIEW.
    Zięba N; Gębka-Kępińska B; Sowa P
    Wiad Lek; 2022; 75(3):735-741. PubMed ID: 35522887
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Severe dyspnoea with alteration of the diffusion capacity of the lung associated with fingolimod treatment.
    Bianco A; Patanella AK; Nociti V; De Fino C; Lucchini M; Savio FL; Rossini PM; Mirabella M
    Mult Scler Relat Disord; 2016 Sep; 9():11-3. PubMed ID: 27645336
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Asymptomatic bradycardia after first fingolimod dose in a pediatric patient with multiple sclerosis - a case report.
    Petruzzo M; Lanzillo R
    Neurol Sci; 2021 May; 42(Suppl 1):37-39. PubMed ID: 33635428
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Retinal hemorrhages following fingolimod treatment for multiple sclerosis; a case report.
    Ueda N; Saida K
    BMC Ophthalmol; 2015 Oct; 15():135. PubMed ID: 26481728
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A tumefactive demyelinating lesion in a person with MS after five years of fingolimod.
    Jeung L; Smits LMG; Hoogervorst ELJ; van Oosten BW; Frequin STFM
    Mult Scler Relat Disord; 2020 May; 40():101978. PubMed ID: 32062445
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy.
    Laroni A; Brogi D; Brescia Morra V; Guidi L; Pozzilli C; Comi G; Lugaresi A; Turrini R; Raimondi D; Uccelli A; Mancardi GL
    Neurol Sci; 2017 Jan; 38(1):53-59. PubMed ID: 27757552
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Five-year results from a phase 2 study of oral fingolimod in relapsing multiple sclerosis.
    Izquierdo G; O'Connor P; Montalban X; von Rosenstiel P; Cremer M; de Vera A; Sfikas N; Francis G; Radue EW; Kappos L
    Mult Scler; 2014 Jun; 20(7):877-81. PubMed ID: 24293455
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fingolimod-related atrioventricular block in paediatric age group with multiple sclerosis: two case reports.
    Kum YE; Pamukçu Ö; Canpolat M
    Cardiol Young; 2023 Nov; 33(11):2384-2386. PubMed ID: 37170775
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early and recurrent macular oedema in a patient treated with fingolimod.
    Cifuentes-Canorea P; Nieves-Moreno M; Sáenz-Francés F; Santos-Bueso E
    Neurologia (Engl Ed); 2019 Apr; 34(3):206-207. PubMed ID: 27776961
    [No Abstract]   [Full Text] [Related]  

  • 37. A case of dextrocardia following maternal exposure to generic Fingolimod during the first trimester of pregnancy.
    Navardi S; Sahraian MA
    Mult Scler Relat Disord; 2018 Apr; 21():69-70. PubMed ID: 29474980
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of Fingolimod-Treatment on Blood Lipid Profiles of Multiple Sclerosis Patients.
    Hovi A; Airas L
    J Neuroimmune Pharmacol; 2016 Dec; 11(4):611-612. PubMed ID: 27388874
    [No Abstract]   [Full Text] [Related]  

  • 39. Combination of teriflunomide and interferon as follow-up therapy after fingolimod-associated PML.
    Fischer-Barnicol B; Oechtering J; Kuhle J; Lorscheider J; Kappos L; Derfuss T
    Neurol Neuroimmunol Neuroinflamm; 2021 Jan; 8(1):. PubMed ID: 33272956
    [No Abstract]   [Full Text] [Related]  

  • 40. The efficacy and safety of fingolimod in patients with relapsing multiple sclerosis: A meta-analysis.
    Yang T; Tian X; Chen CY; Ma LY; Zhou S; Li M; Wu Y; Zhou Y; Cui YM
    Br J Clin Pharmacol; 2020 Apr; 86(4):637-645. PubMed ID: 31869429
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.